Cogent Biosciences Inc. (COGT)
NASDAQ: COGT
· Real-Time Price · USD
13.29
0.04 (0.30%)
At close: Sep 25, 2025, 3:59 PM
13.29
0.00%
After-hours: Sep 25, 2025, 05:10 PM EDT
0.30% (1D)
| Bid | 13.26 |
| Market Cap | 1.86B |
| Revenue (ttm) | 4.29M |
| Net Income (ttm) | -284.08M |
| EPS (ttm) | -2.08 |
| PE Ratio (ttm) | -6.39 |
| Forward PE | -7.03 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 13.34 |
| Volume | 1,235,261 |
| Avg. Volume (20D) | 2,722,214 |
| Open | 13.04 |
| Previous Close | 13.25 |
| Day's Range | 12.97 - 13.49 |
| 52-Week Range | 3.72 - 13.55 |
| Beta | 0.35 |
| Ex-Dividend Date | n/a |
About COGT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol COGT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for COGT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+9%
Cogent Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago
+6.34%
Cogent Biosciences shares are trading higher after the company announced $200 million public offering.
2 months ago · seekingalpha.com
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment ResultsI have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib ...
